Results 171 to 180 of about 288,402 (222)

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu   +18 more
wiley   +1 more source

Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. [PDF]

Clin Exp Med
Xu F, Bao X, Huang W, Zhou K.
europepmc   +1 more source

Immunosuppressive JAG2+ tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells

Cancer Communications, EarlyView.
Abstract Background Tumor‐associated neutrophils (TANs) play a critical role in modulating immune responses and exhibit significant heterogeneity. Our previous study demonstrated that jagged canonical Notch ligand 2 (JAG2)+ TANs were associated with an immunosuppressive microenvironment in high‐grade serous ovarian cancer (HGSOC), but the underlying ...
Chenyang Wang, Moran Yang, Yujing Zhong, Kankan Cao, Xueling Wang, Chen Zhang, Yiying Wang, Mengdi He, Jiaqi Lu, Guodong Zhang, Yan Huang, Haiou Liu   +11 more
wiley   +1 more source

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy. [PDF]

Front Immunol
Li H, Ren C, Cui D, Wu T, Nie Z.
europepmc   +1 more source

Combating cancer immunotherapy resistance: a nano‐medicine perspective

Cancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong, Xintong Xie, Juan Wu, Xiangyu Wang, Wenxiang Zhang, Shuowen Wang, Daria Valerievna Abbasova, Yi Fang, Hongnan Jiang, Jidong Gao, Jing Wang   +10 more
wiley   +1 more source

Mechanisms of photobiomodulation therapy in treating and preventing antineoplastic-induced oral mucositis: a systematic review. [PDF]

Acta Cir Bras
Sales PVA, Godói IPD, Brito GAC, Leitão RC, Araújo AA, Medeiros CACX.   +5 more
europepmc   +1 more source

Cold Atmospheric Plasma in Oncology: A Review and Perspectives on Its Application in Veterinary Oncology. [PDF]

Animals (Basel)
Holanda AGA, Francelino LEC, Moura CEB, Alves Junior C, Matera JM, Queiroz GF.   +5 more
europepmc   +1 more source

Evaluating comparative effectiveness of pembrolizumab-based therapy versus chemotherapy in treatment of gastric carcinoma: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Clin Exp Med
Mansoor H, Gohar M, Attaria A, Karim FF, Naeem U, Khan M, Iqbal J.   +6 more
europepmc   +1 more source

FLOT1 Is a Novel Serum Biomarker of Ovarian Cancer Targeted by N6‐methyladenosine Modification Inhibition

Cell Biology International, EarlyView.
ABSTRACT Ovarian cancer (OC) is a deadly disease and lacks a precise marker for diagnosis worldwide. Our previous work has shown the overexpression of flotillin‐1 (FLOT1) in OC tissue. To improve diagnostic sensitivity and accuracy, we evaluated the serum level of FLOT1 in OC patients and found that the serum concentration of FLOT1 as well as CA125 was
Bin Guan, Qi Lu, Junyu Chen, Jingyi Fang, Zhenyu Liu, Wei Li, Lingyun Zhang, Guoxiong Xu   +7 more
wiley   +1 more source

Balancing immunotherapy and corticosteroids in cancer treatment: dilemma or paradox? [PDF]

Oncologist
Ottaiano A, Santorsola M, Capuozzo M, Scala S.   +3 more
europepmc   +1 more source